Primary lung cancer with radioiodine avidity: A thyroid cancer cohort study

Table 1 Characteristics of the nine patients who received an iodine-131 scan within 1 year before the diagnosis of lung cancer

Patient	Age/gender	Histological type of thyroid cancer	Stage of thyroid cancer	Histological type of lung cancer	Tumor size of lung cancer	Stage of lung cancer	Interval between thyroid cancer and lung cancer diagnosis	Indication and dose of 131I	Interval between 131I administration and lung cancer histological confirmation	131I uptake in lung cancer	NIS expression in lung cancer (staining intensity/percentage)
1	50/F	Papillary	T1aN0bM0	Adenocarcinoma	1.7 cm	T1bN0M0	1.5 yr	Elevated Tg antibody level/30 mCi	5.7 mo	Positive	Weak/60%
2	50/F	Papillary	T1bN0bM0	Adenocarcinoma	2.5 cm	T1bN1M0	15.3 yr	Thyroid remnant ablation/30 mCi	11.3 mo	Negative	Weak/15%
3	47/M	Papillary	T2N1aM0	Adenocarcinoma	2.4 cm	T2aN0M1a	0.2 yr	Elevated Tg level/100 mCi	1.2 mo	Negative	Weak/10%
4	44/F	Papillary	TxN0bM0	Adenocarcinoma	3.2 cm	T4N3M0	18.4 yr	Neck sonography suggesting tumor recurrence/200 mCi	1.8 mo	Negative	Negative
5	66/F	Papillary	TxN0bM0	Adenocarcinoma	2.4 cm	T2aN1M0	10.2 yr	Thyroid cancer surveillance/2 mCi	1.7 mo	Negative	Negative
6	67/M	Papillary	T1bN1bM0	Adenocarcinoma	3.8 cm	T4N2M0	3.0 yr	Elevated Tg level/200 mCi	3.1 mo	Negative	Negative
7	55/F	Papillary	T2N1bM0	Adenocarcinoma	3.0 cm	T1cN0M0	0.3 yr	Thyroid remnant ablation/30 mCi	0.8 mo	Negative	Negative
8	56/F	Papillary	T3aN1aM1	Adenocarcinoma	1.8 cm	T2aN2M0	7.6 yr	Elevated Tg level/100 mCi	3.1 mo	Negative	–
9	69/M	Papillary	T1aN0bM0	Non-small cell lung carcinoma-not otherwise specified	4.3 cm	T2bN2M0	1.0 yr	Elevated Tg level/30 mCi	6.5 mo	Negative	Negative

¹³¹I: Iodine-131; Tg: Thyroglobulin; F: Female; M: Male.